Quesmed wrong answers Flashcards
(165 cards)
What is the definition of COPD?
Chronic obstructive pulmonary disease (COPD) is characterised by irreversible, usually progressive obstruction of the airways. It is an encompassing term for two types of chronic lung diseases: chronic bronchitis and emphysema.
It comprises both:
1. Chronic bronchitis – involves hypertrophy and hyperplasia of the mucus glands in the bronchi
2. Emphysema – involves enlargement of the air spaces and destruction of alveolar walls
There are different phenotypes of COPD dependent on which of these pathologies is more prominent.
What are the risk factors and poor prognostic factors in COPD?
- Tobacco smoking (active or passive)
- Occupational exposure to dust
- Alpha-1 antitrypsin deficiency
Prognosis is worsened by:
-Advancing age
-Ongoing smoking
-Reduced body weight
-Low FEV1
What is the pathophysiology of chronic bronchitis?
- Chronic exposure to noxious particles such as smoking or air pollutants causes hypersecretion of mucus in the large and small bronchi.
- Airway inflammation and fibrotic changes result in narrowing of the airways and subsequently chronic airway obstruction.
- Cigarette smoke interferes with the action of cilia in removing noxious particles.
- Cigarette smoke also dampens the ability of leukocytes in eliminating the bacteria in the airways.
What is the pathophysiology of emphysema?
- Abnormal irreversible enlargement of the airspaces distal to the terminal bronchioles, due to destruction of their walls.
- This reduces the alveolar surface area thus impeding efficient gaseous exchange.
- Cigarette smoke stimulates accumulation of neutrophils and macrophages which produce neutrophil elastase that destroys alveolar walls.
- In a normal lung, α1-antitrypsin is responsible for inhibiting excessive activity of neutrophil elastase. However, in emphysema, the normal balance of proteases and antiproteases is lost. The stimulated neutrophils release free radicals that inhibit the activity of α1-antitrypsin.
- This results in loss of elastic recoil and subsequently airway collapse during expiration and air trapping.
Where in the respiratory tract do 1. cigarette smoke, 2. Alpha-1-antitrypsin deficiency and 3. Fibrosis/atelectasis affect?
- The proximal part of the airways such as the respiratory bronchioles, mainly the upper lobes.
- The entire acini from respiratory bronchioles to alveolar duct and alveoli, mainly the lower lobes.
- The distal part of the airways, mainly the paraseptal region
What are the signs and symptoms of COPD?
Symptoms:
- Productive cough
- Recurrent respiratory infections
- Wheeze
- Dyspnoea
- Reduced exercise tolerance
- Weight loss
Signs
- Accessory muscle use for respiration
- Prolonged expiratory phase
- Pursed lip breathing
- Tachypnoea
- Hyperinflation – reduction of the cricosternal distance
- Reduced chest expansion
- Hyper-resonant percussion
- Decreased/quiet breath sounds
- Wheeze
- Cyanosis
- Cor pulmonale (signs of right heart failure)
How is COPD investigated?
- Bloods
- FBC – polycythaemia due to chronic hypoxia
- ABG – reduced paO2 +/– raised paCO2 (may be acute or compensated type 2 respiratory failure) - ECG
- P-pulmonale (right atrial hypertrophy)
- Right ventricular hypertrophy, if there is cor pulmonale - Chest X-ray
- Hyperinflated chest (>6 anterior ribs)
- Bullae
- Decreased peripheral vascular markings
- Flattened hemidiaphragms - Spirometry – can be performed at diagnosis or to monitor progression
- FEV1/FVC ratio <0.7
- Increased TLC
- Low TLCO – seen in patients who have significant emphysema without a significant chronic bronchitis element
- Reversibility testing is not required unless history/examination fails to differentiate between asthma and COPD
Severity is dependent on the value of FEV1 according to the GOLD criteria.
Other tests:
- Sputum culture – to identify exacerbating organisms
- Brain natriuretic peptide (BNP) + echocardiogram – to assess for heart failure
- Serum alpha-1 antitrypsin – to assess for genetic cause in young patients
- Consider high-resolution CT (HRCT) scan if the diagnosis remains ambiguous
What are the possible differentials for COPD?
The differential diagnosis for COPD includes:
1. Asthma: Characterised by reversible airway obstruction, episodic symptoms and response to bronchodilators.
2. Bronchiectasis: Persistent productive cough, recurrent respiratory infections and abnormal bronchial dilatation on CT chest.
3. Heart Failure: Shortness of breath, orthopnea, paroxysmal nocturnal dyspnoea, and signs of fluid overload such as peripheral oedema and elevated jugular venous pressure.
4. Pulmonary Fibrosis: Progressive dyspnoea, non-productive cough, and inspiratory crackles on auscultation.
What is the non-pharmacological management for COPD?
- Smoking cessation
- Nutritional support
- Flu and pneumococcal vaccinations
- Pulmonary rehabilitation
What are the 4 steps in the pharmacological management of COPD?
- Step 1: short-acting β2 agonist/short-acting muscarinic antagonist – these are continued as the patient goes up the management steps
- Step 2
- For patients with persistent exacerbations but no asthmatic features or evidence of steroid responsiveness:
add a long-acting β2 agonist AND a long-acting muscarinic antagonist
- For patients with persistent exacerbations with asthmatic features or evidence of steroid responsiveness:
increase management to a combination of long-acting β2 agonist and ICS - Step 3
- For patients on a long-acting β2 agonist + long-acting muscarinic antagonist combination who are still getting daily symptoms that affect their activities of daily living:
consider a 3-month trial of long-acting muscarinic antagonist + long-acting β2 agonist + ICS (triple therapy)
*if this does not work, revert back to long-acting β2 agonist + long-acting muscarinic antagonist
- For any patient on step 2 who is getting more than one severe or two moderate exacerbations in a year:
start long-acting muscarinic antagonist + long-acting β2 agonist + ICS - Step 4: if patients are still symptomatic, consider specialist referral
*Other adjuncts: oral theophylline, mucolytic agents, antidepressants.
*Corticosteroids should only be used in acute exacerbations, maintenance doses are not usually recommended.
*Consider LTOT for eligible patients
What are the indications for surgery in COPD?
Patients with severe COPD who remain breathless despite maximal medical therapy should be considered for lung volume reduction surgery if:
- they have upper lobe-predominant emphysema
- FEV1 >20% predicted
- paCO2 <7.3 kPa
- TLCO >20% predicted
Other surgical options include single bullectomy and single- or double-lung transplantation.
How is an acute exacerbation of COPD managed?
- Ensure a patent airway
- Ensure oxygen saturations of 88–92% (if there is a history of CO2 retention)
- Nebulisers – salbutamol, ipratropium
- Steroids – oral prednisolone or IV hydrocortisone (if severe)
- Antibiotics if any evidence of infection (eg. fever or raised inflammatory markers)
Monitor closely for signs of type 2 respiratory failure: drowsiness, asterixis, agitation as this may indicate the need for noninvasive ventilation (BiPaP).
Treatment escalation plans should be closely considered for these patients.
What is T2DM?
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic condition characterized by inadequate insulin production from pancreatic beta cells, resulting in insulin resistance. This leads to an elevation in blood glucose levels, causing hyperglycaemia.
What is the aetiology of type 2 DM?
T2DM results from a combination of genetic and environmental factors. Known contributors include:
- Poor dietary habits
- Lack of physical activity
- Obesity
What are the signs and symptoms of type 2 DM?
Individuals with T2DM may initially be asymptomatic, but over time, they may develop:
- Polyuria
- Polydipsia
- Unexplained weight loss
- Blurry vision
- Fatigue
What are the possible differentials for type 2 DM?
The primary differentials for T2DM include Type 1 Diabetes Mellitus, Maturity Onset Diabetes of the Young (MODY), and Secondary Diabetes Mellitus. The main distinguishing features of these differentials are:
- Type 1 Diabetes Mellitus: Early onset (typically in childhood or adolescence), often presents with ketoacidosis, and requires insulin therapy from diagnosis.
- MODY: Early onset (typically before 25 years), non-insulin dependent, and often has a strong family history.
- Secondary Diabetes Mellitus: Often presents with other signs of pancreatic disease (e.g., pancreatitis, cystic fibrosis), or due to certain medications (e.g., glucocorticoids, antipsychotics).
How is type 2 DM investigated?
If symptomatic, one of the following results is sufficient for diagnosis:
- Random blood glucose ≥ 11.1mmol/l
- Fasting plasma glucose ≥ 7mmol/l
- 2-hour glucose tolerance ≥ 11.1mmol/l
- HbA1C ≥ 48mmol/mol (6.5%)
If the patient is asymptomatic, two results are required from different days.
How is type 2 diabetes managed?
- Lifestyle modifications: Advice on diet, regular physical activity, and smoking cessation
- Pharmacological interventions:
- Initial drug treatment is usually metformin, with consideration of other agents like Pioglitazone, DPP‑4 inhibitors, sulphonylureas, or SGLT-2 inhibitors for those who cannot take metformin.
- Following initial management, consider dual therapy with metformin, pioglitazone, a DPP‑4 inhibitor or a sulphonylurea (such as gliclizide).
- If dual therapy has not controlled drug glucose, triple therapy using the above medications can be considered. Otherwise, starting insulin may be necessary. - Close Monitoring: Measure HbA1c levels at 3-6 month intervals. If the patient is on insulin or is at risk of hypoglycaemia, self-monitoring of glucose at home is necessary.
DPP-4 inhibitors: Mechanism, names, contraindications
These inhibit the enzyme DPP-4 which normally destroys the hormone incretin (GLP-1).
Incretin stimulates insulin secretion from the beta cells and inhibits glucagon release by the alpha cells.
Therefore, inhibition of the breakdown of incretin leads to higher incretin levels and therefore insulin levels (as well as lower glucagon levels).
‘Gliptins’ eg alogliptin, linagliptin, saxagliptin, sitagliptin
CI in ketoacidosis, reduce in renal impairment (not linagliptin), and hepatic impairment (not linagliptin or sitagliptin)
Thiazolidinediones (glitazones): Mechanism, names, contraindications
Promotes insulin sensitivity and improves uptake of glucose through agonism at the peroxisome-proliferator-activated receptor gamma (PPARG).
Pioglitazone
CI in ketoacidosis, hx of HF, previous/active bladder cancer, haematuria, hepatic impairment. Fallen out of favour in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.
SGLT2-inhibitors: Mechanism, names, contraindications
Bind to SGLT2 in the luminal membrane in the early segments of the nephron where they block glucose resorption.
‘Flozins’ - Canaglifozin, Dapagliflozin, Empagliflozin, Ertuglifozin
CI in ketoacidosis. Caution or avoid with renal or hepatic impairment.
Sulphonylureas: Mechanism, names, contraindications
Stimulate insulin production from beta cell (by closing ATP-sensitive K-channels in the beta cell membrane that result in insulin release
Gliclazide, Glimepiride, Glipizide, Tolbutamide
CI in ketoacidosis, has a moderate/high risk of hypoglycaemia, particularly in older people. Caution or avoid in hepatic or renal impairment.
Which insulin therapy might be used in Type 2 DM?
NICE guidance recommends basal insulin therapy with isophane (NPH) insulin as the first type to be used as it is most cost effective eg. Insulatard. Quick acting insulin analogues eg. Humalog, Novorapid, may be added in with meals if there is a big post meal glucose excursion.
Long acting insulin analogues include Levemir, Lantus, Insulin Degludec and Abasaglar (a biosimilar insulin).
Mixed insulin combination which contain varying proportions of short and intermediate acting insulin such as Novomix 30 (30% short acting, 70% intermediate acting insulin) are more convenient because of fewer injections per day but may not be as successful.
What are the possible complications of diabetes mellitus?
- Gastrointestinal Complications: Gastroparesis - a result of poor glycaemic control leading to nerve damage of the autonomic nervous system. Characterized by delayed gastric emptying, early satiety, abnormal stomach wall movements, and morning nausea.
- Neurological Complications: Autonomic Neuropathy - may lead to postural hypotension and associated symptoms like dizziness, falls, and loss of consciousness.
- Vascular Complications: Peripheral Arterial Disease (PAD) - patients present with foot discolouration, gangrene, intermittent claudication, rest pain, night pain and absent peripheral pulses (confirmed on doppler).
- Foot Complications: Diabetic Foot Infections - patients with vascular and neuropathic complications are at high risk for diabetic foot ulceration and subsequent infection.
- Sexual Dysfunction - caused by a combination of factors including poor glycaemic control, neuropathy, microvascular complications, obesity, hypertension, depression, medication side effects, etc.
- Cardiac Complications - diabetes significantly increases the risk of cardiovascular disease, contributing to major morbidity and mortality.